| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/AJT.13838 |
| P698 | PubMed publication ID | 27106124 |
| P2093 | author name string | A Miller | |
| S Martin | |||
| B A Kiberd | |||
| K K Tennankore | |||
| P2860 | cites work | The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients | Q26774993 |
| Proteasome inhibitor-based therapy for antibody-mediated rejection | Q26830410 | ||
| Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States | Q26866026 | ||
| Utility of HLA Antibody Testing in Kidney Transplantation | Q35790601 | ||
| Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival. | Q36514864 | ||
| Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation | Q37375622 | ||
| Prevention and treatment of alloantibody-mediated kidney transplant rejection | Q37914943 | ||
| Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation | Q38108524 | ||
| Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options | Q38206175 | ||
| Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold | Q39268069 | ||
| Incidence and impact of de novo donor-specific alloantibody in primary renal allografts | Q39472834 | ||
| Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information. | Q40990548 | ||
| Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure | Q42171636 | ||
| Screening to prevent polyoma virus nephropathy: a medical decision analysis | Q45423889 | ||
| Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation | Q45627897 | ||
| Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. | Q45972310 | ||
| Treatment of symptomatic transplant glomerulopathy with rituximab. | Q46005396 | ||
| Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study. | Q51002006 | ||
| Predicting kidney graft failure by HLA antibodies: a prospective trial. | Q51038562 | ||
| Cost-effectiveness of colorectal cancer screening in renal transplant recipients. | Q51114850 | ||
| A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. | Q51432032 | ||
| Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. | Q53388181 | ||
| Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. | Q53459320 | ||
| A study of the quality of life and cost-utility of renal transplantation. | Q53621261 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | decision analysis | Q5249226 |
| P304 | page(s) | 3212-3219 | |
| P577 | publication date | 2016-04-23 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | De Novo Donor-Specific Human Leukocyte Antigen Antibody Screening in Kidney Transplant Recipients After the First Year Posttransplantation: A Medical Decision Analysis | |
| P478 | volume | 16 |
| Q57143685 | Biomarkers and Pharmacogenomics in Kidney Transplantation |
| Q37641415 | Changing Paradigms in the Management of Rejection in Kidney Transplantation: Evolving From Protocol-Based Care to the Era of P4 Medicine |
| Q38967641 | Higher calcineurin inhibitor levels predict better kidney graft survival in patients with de novo donor-specific anti-HLA antibodies: a cohort study |
| Q49813842 | Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization |
| Q50504222 | Utility of protocol kidney biopsies for de novo donor-specific antibodies. |
Search more.